The burden of RSV-associated illness in children aged < 5 years, South Africa, 2011 to 2016

BACKGROUND: Vaccines and monoclonal antibodies to protect the very young infant against the respiratory syncytial virus (RSV)-associated illness are effective for limited time periods. We aimed to estimate age-specific burden to guide implementation strategies and cost-effectiveness analyses. METHOD...

Descripción completa

Detalles Bibliográficos
Autores principales: Moyes, Jocelyn, Tempia, Stefano, Walaza, Sibongile, McMorrow, Meredith L., Treurnicht, Florette, Wolter, Nicole, von Gottberg, Anne, Kahn, Kathleen, Cohen, Adam L., Dawood, Halima, Variava, Ebrahim, Cohen, Cheryl
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10088270/
https://www.ncbi.nlm.nih.gov/pubmed/37038125
http://dx.doi.org/10.1186/s12916-023-02853-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10088270/
https://www.ncbi.nlm.nih.gov/pubmed/37038125
http://dx.doi.org/10.1186/s12916-023-02853-3

Ejemplares similares